ZA984697B
(en)
*
|
1997-06-13 |
1999-12-01 |
Lilly Co Eli |
Stable insulin formulations.
|
US6211144B1
(en)
*
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
JP2002535967A
(ja)
|
1999-01-06 |
2002-10-29 |
ジェネンテック・インコーポレーテッド |
インシュリン様成長因子(igf)i変異体
|
PT1141014E
(pt)
|
1999-01-06 |
2005-04-29 |
Genentech Inc |
Variante mutante do factor de crescimento semelhante a insulina (igf-i)
|
CA2369451C
(en)
|
1999-04-08 |
2009-09-22 |
Genentech, Inc. |
Composition based on oppositely-charged polypeptides
|
US20040220103A1
(en)
*
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US6746853B1
(en)
|
1999-05-19 |
2004-06-08 |
Xencor, Inc. |
Proteins with insulin-like activity useful in the treatment of diabetes
|
US7169889B1
(en)
*
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
US7022674B2
(en)
*
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
WO2001052937A1
(en)
*
|
2000-01-24 |
2001-07-26 |
Medtronic Minimed, Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
EP1292324A2
(en)
*
|
2000-05-05 |
2003-03-19 |
Novo Nordisk A/S |
Critical illness neuropathy
|
EP1282437B1
(en)
|
2000-05-16 |
2008-03-19 |
Genentech, Inc. |
Treatment of cartilage disorders
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
WO2002067969A2
(en)
|
2001-02-21 |
2002-09-06 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
US7713932B2
(en)
*
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
DE60224284T2
(de)
|
2001-06-28 |
2008-12-18 |
Novo Nordisk A/S |
Stabile formulierung von modifiziertem glp-1
|
US6737401B2
(en)
*
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7030082B2
(en)
*
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US20030068361A1
(en)
*
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
US20030199445A1
(en)
*
|
2002-02-07 |
2003-10-23 |
Knudsen Lotte Bjerre |
Use of GLP-1 compound for treatment of critically ill patients
|
ES2360182T3
(es)
*
|
2002-05-07 |
2011-06-01 |
Novo Nordisk A/S |
Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
ITMI20021684A1
(it)
*
|
2002-07-29 |
2004-01-29 |
Therapicon Srl |
Composizione farmaceutica di peptide nasale
|
KR101123113B1
(ko)
*
|
2002-07-29 |
2012-03-15 |
쎄라피콘 에스.알.엘. |
코 펩티드 약학 제형
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
WO2004105790A1
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
CN104826116A
(zh)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
CA2580313C
(en)
|
2004-07-19 |
2016-03-15 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
EP1789074A4
(en)
*
|
2004-08-09 |
2009-08-12 |
Alios Biopharma Inc |
PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
CN106137952B
(zh)
|
2004-11-12 |
2020-11-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
JP4874989B2
(ja)
*
|
2004-11-22 |
2012-02-15 |
ノヴォ ノルディスク アー/エス |
可溶性で安定なインスリン含有調合物
|
KR101366482B1
(ko)
|
2004-12-27 |
2014-02-21 |
사일런스 테라퓨틱스 아게 |
코팅된 지질 복합체 및 이들의 용도
|
EP1862174A1
(en)
*
|
2005-03-02 |
2007-12-05 |
Ajinomoto Co., Inc. |
Inhibitor for insulin polymer formation
|
JP2008542235A
(ja)
*
|
2005-05-25 |
2008-11-27 |
ノボ・ノルデイスク・エー/エス |
安定化ポリペプチド製剤
|
US8097584B2
(en)
*
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CA2626357A1
(en)
*
|
2005-10-20 |
2007-04-26 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of rapid acting insulin
|
EP2505593A1
(en)
|
2005-12-28 |
2012-10-03 |
Novo Nordisk A/S |
Compositions comprising an acylated insulin and zinc and method of making the said compositions
|
WO2007121318A2
(en)
*
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
CA2649630C
(en)
*
|
2006-04-20 |
2016-04-05 |
Silence Therapeutics Ag |
Lipoplex formulations for specific delivery to vascular endothelium
|
EA030606B1
(ru)
|
2006-05-04 |
2018-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы приготовления лекарственного средства, содержащего полиморфы
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
WO2007135117A2
(en)
*
|
2006-05-24 |
2007-11-29 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations
|
US9023793B2
(en)
*
|
2006-09-29 |
2015-05-05 |
Retrophin, Inc. |
Intranasal carbetocin formulations and methods for the treatment of autism
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
US8114428B2
(en)
*
|
2007-03-08 |
2012-02-14 |
Sbf Synthetic Bone Factory Gmbh |
Methods for manufacturing a composition for treating bone and/or cartilage defects
|
WO2008118387A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Wayne State University |
Erythrocyte atp-release modulators
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
BRPI0818004B8
(pt)
*
|
2007-10-16 |
2021-05-25 |
Biocon Ltd |
composição farmacêutica sólida administrável por via oral e o processo da mesma.
|
US8986253B2
(en)
|
2008-01-25 |
2015-03-24 |
Tandem Diabetes Care, Inc. |
Two chamber pumps and related methods
|
WO2009115469A1
(en)
|
2008-03-18 |
2009-09-24 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
TWI394580B
(zh)
*
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
EP2283027B2
(en)
|
2008-05-01 |
2018-04-18 |
Arecor Limited |
Protein formulation
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
EP2328607A1
(en)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
ES2477552T3
(es)
|
2008-09-08 |
2014-07-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
|
EP2344195A2
(en)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Combination therapy for the treatment of diabetes and related conditions
|
US8408421B2
(en)
|
2008-09-16 |
2013-04-02 |
Tandem Diabetes Care, Inc. |
Flow regulating stopcocks and related methods
|
CA2737461A1
(en)
|
2008-09-19 |
2010-03-25 |
Tandem Diabetes Care, Inc. |
Solute concentration measurement device and related methods
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
WO2010043566A2
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem insulin und einem glp-1-agonisten
|
EP2349279A4
(en)
|
2008-10-28 |
2013-12-25 |
Univ Leland Stanford Junior |
ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
|
ES2607003T3
(es)
|
2008-10-30 |
2017-03-28 |
Novo Nordisk A/S |
Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
|
BRPI0923121A2
(pt)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Formas salinas de compostos orgânico
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
CA2750252A1
(en)
|
2009-01-28 |
2010-08-05 |
Smartcells, Inc. |
Synthetic conjugates and uses thereof
|
PE20120582A1
(es)
|
2009-01-28 |
2012-05-26 |
Smartcells Inc |
Conjugados de insulina cristalina
|
SG173112A1
(en)
|
2009-01-28 |
2011-08-29 |
Smartcells Inc |
Conjugate based systems for controlled drug delivery
|
AU2010208381A1
(en)
|
2009-01-28 |
2011-08-04 |
Smartcells, Inc. |
Exogenously triggered controlled release materials and uses thereof
|
US20110293562A1
(en)
|
2009-02-12 |
2011-12-01 |
Proyecto De Biomedicina Cima, S.L. |
Use of cardiotrophin-1 for the treatment of metabolic diseases
|
US9250106B2
(en)
|
2009-02-27 |
2016-02-02 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
AU2010217760B2
(en)
|
2009-02-27 |
2015-04-09 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
AU2010226243A1
(en)
|
2009-03-20 |
2011-09-22 |
Smartcells, Inc. |
Terminally-functionalized conjugates and uses thereof
|
US8569231B2
(en)
|
2009-03-20 |
2013-10-29 |
Smartcells, Inc. |
Soluble non-depot insulin conjugates and uses thereof
|
CA2764423A1
(en)
*
|
2009-06-26 |
2010-12-29 |
Novo Nordisk A/S |
Preparation comprising insulin, nicotinamide and an amino acid
|
EP2459251B1
(en)
|
2009-07-30 |
2014-03-12 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
US9707176B2
(en)
|
2009-11-13 |
2017-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist and methionine
|
ES2855146T3
(es)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
ES2760917T3
(es)
|
2009-11-27 |
2020-05-18 |
Boehringer Ingelheim Int |
Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
|
CN101912600B
(zh)
*
|
2010-01-11 |
2014-01-29 |
杨国汉 |
改善胰岛素在溶液中稳定性的方法
|
JP6034781B2
(ja)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
併用療法
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
EA201991014A1
(ru)
|
2010-06-24 |
2019-09-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение диабета
|
AU2011282988A1
(en)
|
2010-07-28 |
2013-01-31 |
Smartcells, Inc. |
Recombinantly expressed insulin polypeptides and uses thereof
|
JP2013541500A
(ja)
|
2010-07-28 |
2013-11-14 |
スマートセルズ・インコーポレイテツド |
組換えレクチン、結合部位修飾レクチンおよびそれらの用途
|
EP2598170A4
(en)
|
2010-07-28 |
2016-07-06 |
Smartcells Inc |
MEDICAMENT-LIGAND CONJUGATES, THEIR SYNTHESIS AND CORRESPONDING INTERMEDIATES
|
PT2611458T
(pt)
|
2010-08-30 |
2016-12-16 |
Sanofi Aventis Deutschland |
Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
|
RU2013123515A
(ru)
|
2010-10-27 |
2014-12-10 |
Ново Нордиск А/С |
Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN102188367B
(zh)
*
|
2011-01-05 |
2012-11-07 |
山东新时代药业有限公司 |
一种甘精胰岛素注射液及其制备方法
|
US10457659B2
(en)
|
2011-04-29 |
2019-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for increasing proliferation of adult salivary stem cells
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130345113A1
(en)
*
|
2011-07-13 |
2013-12-26 |
Ronald E. Strohbehn |
Method of Use of Activated Functional Proteins to Improve Animal Health
|
MX366629B
(es)
|
2011-07-15 |
2019-07-17 |
Boehringer Ingelheim Int |
Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
|
PT2750699E
(pt)
|
2011-08-29 |
2015-11-03 |
Sanofi Aventis Deutschland |
Acelerómetro pendular
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
KR102007057B1
(ko)
*
|
2011-10-31 |
2019-08-02 |
엑스에리스 파머수티클스, 인크. |
당뇨병 치료를 위한 제형물
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9555186B2
(en)
|
2012-06-05 |
2017-01-31 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
CA2890048C
(en)
|
2012-12-03 |
2022-05-03 |
Merck Sharp & Dohme Corp. |
O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
|
CN104994864B
(zh)
*
|
2012-12-19 |
2018-05-29 |
沃克哈特有限公司 |
包含人胰岛素或其类似物或衍生物的稳定水性组合物
|
JP2016505601A
(ja)
|
2012-12-26 |
2016-02-25 |
ウォックハート リミテッド |
医薬組成物
|
TWI780236B
(zh)
*
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US10201656B2
(en)
|
2013-03-13 |
2019-02-12 |
Tandem Diabetes Care, Inc. |
Simplified insulin pump for type II diabetics
|
CN105358531B
(zh)
|
2013-03-14 |
2017-11-14 |
利兰-斯坦福大学初级学院的董事会 |
线粒体醛脱氢酶‑2调节剂和其使用方法
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
US9492608B2
(en)
|
2013-03-15 |
2016-11-15 |
Tandem Diabetes Care, Inc. |
Method and device utilizing insulin delivery protocols
|
CA2907848A1
(en)
|
2013-04-03 |
2014-10-09 |
Sanofi |
Treatment of diabetes mellitus by long-acting formulations of insulins
|
US10137172B2
(en)
|
2013-04-30 |
2018-11-27 |
Novo Nordisk A/S |
Administration regime
|
EP3016704A4
(en)
*
|
2013-07-04 |
2017-03-08 |
Insuline Medical Ltd. |
Device, system and method for delivery of a long-acting drug
|
BR112016007176A2
(pt)
|
2013-10-04 |
2018-01-23 |
Merck Sharp & Dohme |
conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
|
TW201605489A
(zh)
|
2013-10-25 |
2016-02-16 |
賽諾菲公司 |
賴谷胰島素(insulin glulisine)的穩定調配物
|
CN112957455A
(zh)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
SG11201604706TA
(en)
*
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
WO2015104311A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
CN106102763A
(zh)
*
|
2014-01-13 |
2016-11-09 |
塞尔玛琳糖尿病有限责任公司 |
速效胰岛素制剂和药物递送系统
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
CN107206058A
(zh)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
甘精胰岛素/利西拉来固定比率配制剂
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
CN105535942B
(zh)
*
|
2016-01-28 |
2017-07-28 |
通化东宝药业股份有限公司 |
一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
|
WO2017145104A1
(en)
*
|
2016-02-25 |
2017-08-31 |
Wockhardt Limited |
Pharmaceutical composition of insulin glargine and amino acids
|
JP2019517542A
(ja)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
リナグリプチンおよびメトホルミンの組合せ
|
HUE055231T2
(hu)
|
2016-12-16 |
2021-11-29 |
Novo Nordisk As |
Inzulint tartalmazó gyógyászati készítmények
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
TWI762706B
(zh)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
EP3740212A4
(en)
|
2017-12-18 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
|
EP3727424A4
(en)
|
2017-12-18 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
CN110063932A
(zh)
*
|
2019-04-12 |
2019-07-30 |
浙江大学 |
一种多肽蛋白类药物的缓释组合物制剂及其制备方法
|
WO2021144476A1
(en)
|
2020-02-18 |
2021-07-22 |
Novo Nordisk A/S |
Pharmaceutical formulations
|
PE20230457A1
(es)
|
2020-03-31 |
2023-03-10 |
Protomer Tech Inc |
Conjugados para reactividad selectiva a dioles vecinales
|
EP4247429A1
(en)
|
2020-11-19 |
2023-09-27 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and insulin analogs
|
WO2023017537A1
(en)
|
2021-08-12 |
2023-02-16 |
Celagenex Research (India) Pvt. Ltd. |
Oral algal oil based gastro-intestinal tract permeable peptide composition
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|